{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:26:48Z","timestamp":1786728408073,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Majority of the gallbladder cancer (GBC) cases are diagnosed at an advanced stage where chemotherapy alone (or in combination with other treatment methods) is mainly opted as therapeutic approach. However, success or failure of this approach largely depends on the interindividual genetic differences. Careful consideration on the genetic association could assist in the evaluation of patient\u2019s treatment response and survival rate. Hence, the present study aims to investigate the survival of patients with GBC and their treatment response to gemcitabine and cisplatin\/carboplatin-based chemotherapy in association with Glutathione S-transferase (GSTs) gene polymorphism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods:<\/jats:title>\n                    <jats:p>\n                      A total of 216 histologically confirmed cases of gallbladder cancer were recruited. A total of 180 patients were treated with gemcitabine and cisplatin\/carboplatin-based chemotherapy.\n                      <jats:italic toggle=\"yes\">GSTM1, GSTT1,<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">GSTP1<\/jats:italic>\n                      genotypes were determined by multiplex PCR and by PCR restriction fragment length polymorphism (PCR-RFLP), respectively. The influence of genetic polymorphism on overall survival was analyzed by Kaplan\u2013Meier method, survival rate difference was analyzed by log-rank test, and hazard ratio for mortality outcomes was estimated using Cox regression method.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      GBC patients having genotype\n                      <jats:italic toggle=\"yes\">GSTP1<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">AG + GG<\/jats:italic>\n                      ) showed poor 3-year survival rate of 0.8% compared to 10.9% of GSTP1 (\n                      <jats:italic toggle=\"yes\">AA<\/jats:italic>\n                      ) genotype (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      = 6.456,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.011). The multivariate Cox regression results showed that the death risk was significantly higher in\n                      <jats:italic toggle=\"yes\">GSTP1 (AG + GG)<\/jats:italic>\n                      genotype (HR = 3.858,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.050). We found no association of\n                      <jats:italic toggle=\"yes\">GSTM1<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">GSTT1<\/jats:italic>\n                      gene polymorphism with the survival; however, the combined genotypes of\n                      <jats:italic toggle=\"yes\">GSM1\/GSTP1, GSTT1\/GSTP1,<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">GSTM1\/GSTT1\/GSTP1<\/jats:italic>\n                      were associated with survival (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.053, 0.006, and 0.058, respectively). Increased death hazard was noted by the genotype combinations of\n                      <jats:italic toggle=\"yes\">GSTM1+\/GSTP1AG + GG<\/jats:italic>\n                      (HR = 3.484,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.024),\n                      <jats:italic toggle=\"yes\">GSTM1-\/GSTP1AG + GG<\/jats:italic>\n                      (HR = 2.721,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.014),\n                      <jats:italic toggle=\"yes\">GSTT1+\/GSTP1AG + GG<\/jats:italic>\n                      (HR = 20.690,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001), and\n                      <jats:italic toggle=\"yes\">GSTT1-\/GSTP1AA<\/jats:italic>\n                      (HR = 26.111,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001). Our findings indicate that chemotherapy treatment response of\n                      <jats:italic toggle=\"yes\">GSTP1 (AG + GG<\/jats:italic>\n                      ) has 1.62-fold increased risk for progression compared to\n                      <jats:italic toggle=\"yes\">GSTP1 (AA<\/jats:italic>\n                      ) genotype (p = 0.018); however, none of the genotypes showed association with overall survival and death risk after chemotherapeutic treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      We found that the presence of\n                      <jats:italic toggle=\"yes\">GSTP1 (<\/jats:italic>\n                      <jats:italic toggle=\"yes\">AG + GG)<\/jats:italic>\n                      genotype showed survival disadvantage and poor treatment outcomes in response to gemcitabine and cisplatin\/carboplatin-based chemotherapy. This could serve as biomarker, and future research in pharmacogenomics will definitely pave the way for the development of better treatment approach for GBC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1897_22","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T15:00:38Z","timestamp":1711810838000},"page":"289-296","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Survival analysis in association with GST gene polymorphism and Treatment outcomes of Gemcitabine and Cisplatin\/Carboplatin-based chemotherapy among patients with Gallbladder Carcinoma"],"prefix":"10.4103","volume":"20","author":[{"given":"Zainab","family":"Feroz","sequence":"first","affiliation":[{"name":"Department of Biochemistry, University of Allahabad, Prayagraj, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishabh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Allahabad, Prayagraj, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Kamala Nehru Memorial Hospital, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munish","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Allahabad, Prayagraj, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"R1-20260507","doi-asserted-by":"crossref","first-page":"106234","DOI":"10.1016\/j.ijsu.2022.106234","article-title":"Current management of incidental gallbladder cancer: A review","volume":"98","author":"Feo","year":"2022","journal-title":"Int J Surg"},{"key":"R2-20260507","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1007\/s00261-020-02871-2","article-title":"Current update on gallbladder carcinoma","volume":"46","author":"Ganeshan","year":"2021","journal-title":"Abdom Radiol"},{"key":"R3-20260507","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.3390\/cancers13205074","article-title":"Quality of life and symptom management in advanced biliary tract cancers","volume":"13","author":"Hunter","year":"2021","journal-title":"Cancer (Basel)"},{"key":"R4-20260507","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.canlet.2018.06.028","article-title":"The multifaceted role of glutathione S-transferases in cancer","volume":"433","author":"Chatterjee","year":"2018","journal-title":"Cancer Lett"},{"key":"R5-20260507","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/03602532.2011.552912","article-title":"Regulatory functions of glutathione S-transferase P1-1 unrelated to detoxification","volume":"43","author":"Tew","year":"2011","journal-title":"Drug Metab Rev"},{"key":"R6-20260507","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.3390\/nu11081741","article-title":"Glutathione S-transferase P1-1 an enzyme useful in biomedicine and as biomarker in clinical practice and in environmental pollution","volume":"11","author":"Bocedi","year":"2019","journal-title":"Nutrients"},{"key":"R7-20260507","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1089\/ars.2012.4920","article-title":"Redox environment, free radical and oxidative damage","volume":"18","author":"Storr","year":"2013","journal-title":"Antioxid Redox Signal"},{"key":"R8-20260507","first-page":"527","article-title":"Glutathione S-transferase M1, T1, P1 polymorphsims and survival among Lung cancer patients","volume":"12","author":"Sweeney","year":"2003","journal-title":"Cancer Epidermal Biomarkers Prev"},{"key":"R9-20260507","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12885-019-6507-2","article-title":"Long-term outcomes of surgical resection for T1b gallbladder cancer: An institutional evaluation","volume":"20","author":"Yuza","year":"2020","journal-title":"BMC Cancer"},{"key":"R10-20260507","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/13543784.2021.1928636","article-title":"Targeted therapies for gallbladder cancer: An overview of agents in preclinical and clinical development","volume":"30","author":"Lorenzo","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"R11-20260507","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41389-017-0025-3","article-title":"Glutathione S-transferases: Substrates, inhibitor and pro-drugs in cancer and neurodegenerative diseases","volume":"7","author":"Allocati","year":"2018","journal-title":"Oncogenesis"},{"key":"R13-20260507","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0304-3835(96)04832-X","article-title":"A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies","volume":"107","author":"Abdel-Rehman","year":"1996","journal-title":"Cancer Lett"},{"key":"R14-20260507","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/carcin\/18.4.641","article-title":"Identification of genetic polymorphism at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer","volume":"18","author":"Harries","year":"1997","journal-title":"Carcinogenesis"},{"key":"R15-20260507","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1158\/1078-0432.CCR-04-2333","article-title":"Association of GSTP1 polymorphism and survival for esophageal cancer","volume":"11","author":"Lee","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R16-20260507","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1177\/09603271211059496","article-title":"GSTP1 Ile105 Val polymorphism among North Indian lung cancer patients treated using monotherapy and poly-pharmacy","volume":"40","author":"Walia","year":"2021","journal-title":"Hum Exp Toxicol"},{"key":"R17-20260507","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3346\/jkms.2010.25.6.846","article-title":"Genetic polymorphism of GSTP1: Prediction of clinical outcome to oxoplatin\/5-FU-based chemotherapy in advanced gastric cancer","volume":"25","author":"Li","year":"2010","journal-title":"J Korean Med Sci"},{"key":"R18-20260507","doi-asserted-by":"crossref","first-page":"9139","DOI":"10.1007\/s13277-015-4780-5","article-title":"Association of DNA repair and xenobiotic pathway gene polymorphisms with genetic susceptibility to gastric cancer patients in West Bengal, India","volume":"37","author":"Ghosh","year":"2016","journal-title":"Tumour Biol"},{"key":"R19-20260507","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.22468","article-title":"Glutathione S-transferase gene polymorphisms and risk and survival of pancreatic cancer","volume":"109","author":"Jiao","year":"2007","journal-title":"Cancer"},{"key":"R20-20260507","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ygyno.2005.08.035","article-title":"Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival","volume":"100","author":"Beeghly","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R21-20260507","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/cncr.21619","article-title":"Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma","volume":"106","author":"Lu","year":"2006","journal-title":"Cancer"},{"key":"R22-20260507","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.31557\/APJCP.2020.21.8.2251","article-title":"Frequency and association of GSTM1 and GSTT1 gene polymorphisms with survival in breast cancer patients","volume":"21","author":"Tangkheunkhan","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"key":"R23-20260507","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.urolonc.2013.05.010","article-title":"Impact of CYP1A1, GSTM1, and GSTT1 polymorphisms in overall and specific prostate cancer survival","volume":"32","author":"Acevedo","year":"2014","journal-title":"Urol Oncol"},{"key":"R24-20260507","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.urolonc.2017.02.005","article-title":"GSTM1 genotype is an independent prognostic factor in clear cell renal cell carcinoma","volume":"35","author":"Coric","year":"2017","journal-title":"Urol Oncol"},{"key":"R25-20260507","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/cncr.25006","article-title":"Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients","volume":"116","author":"Kilburn","year":"2010","journal-title":"Cancer"},{"key":"R26-20260507","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejca.2006.09.011","article-title":"The role of glutathione-S-transferase polymorphisms in ovarian cancer survival","volume":"43","author":"Nagle","year":"2007","journal-title":"Eur J Cancer"},{"key":"R27-20260507","first-page":"587","article-title":"The Glutathione S-Transferase M1 genotype in ovarian cancer","volume":"9","author":"Lallas","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R28-20260507","first-page":"45","article-title":"Role of glutathione S-transferase enzymes in toxicology, pharmacology and human disease","author":"Olvera-Bello","year":"2010","journal-title":"Xenobiotic Metabolizing Enzymes and Xenobiotic Receptors. Pharmacological and Toxicological Aspects"},{"key":"R29-20260507","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1023\/A:1026036521852","article-title":"Does glutathione S-transferase Pi (GST-Pi) a marker protein for cancer?","volume":"253","author":"Aliya","year":"2003","journal-title":"Mol Cell Biochem"},{"key":"R30-20260507","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4238\/gmr.15037668","article-title":"Role of GSTM1, GSTT1, and GSTP1 IIe105Val gene polymorphisms in the response to chemotherapy and overall survival of advanced non-small cell lung cancer","volume":"15","author":"Jia","year":"2016","journal-title":"Genet Mol Res"},{"key":"R31-20260507","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.canep.2009.08.004","article-title":"Glutathione S-transferase polymorphisms and survival in African-American and white colorectal cancer patients","volume":"33","author":"Jones","year":"2009","journal-title":"Cancer Epidemiol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1897_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:26:39Z","timestamp":1786724799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1897_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1897_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"assertion":[{"value":"2022-09-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}